A clinical risk score for prediction of stent thrombosis

被引:26
作者
Baran, Kenneth W. [1 ]
Lasala, John M. [2 ]
Cox, David A. [3 ]
Song, Aijun [4 ]
Deshpande, Mahesh C. [4 ]
Jacoski, Mary V. [4 ]
Mascloli, Stephen R. [4 ]
机构
[1] St Paul Heart Clin, St Paul, MN USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Lehigh Valley Heart Specialists, Allentown, PA USA
[4] Boston Sci Corp, Natick, MA USA
关键词
D O I
10.1016/j.amjcard.2008.04.068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim was to develop a clinically useful patient risk score predictive for stent thrombosis (ST). Using readily available baseline clinical and angiographic characteristics, a Cox proportional hazards multivariate model was used to identify significant (p < 0.10) predictors of ST through I year in 2,487 patients receiving a TAXUS Express (Boston Scientific Corp., Natick, Massachusetts) drug-eluting stent (DES) in the ARRIVE I registry. Hazard ratios of significant predictors were rounded to an integer value ranging from 2 to 5. These values were summed for a maximum possible score of 24. The model was validated using 1-year data from a similar DES data set (ARRIVE 2, n = 4,820 patients). The 8 significant predictors found were thienopyridine therapy discontinuation before 6 months, insulin-requiring diabetes, smoker at baseline, left main stent placement, multiple stent placement, lesion length > 28 mm, moderate to severe lesion calcification, and reference vessel diameter < 3 mm. Model discrimination was high, indicated by an area under the receiver-operator characteristic curve of 0.819. Stratification of patients into low-, medium-, and high-risk groups showed that ST developed in 0.8% of patients with a score < 6, 3.6% of patients with a score of 7 to 13, and 12.6% of patients with a score >= 14. In conclusion, using 8 readily available clinical and angiographic characteristics, we defined an ST risk score for patients receiving a DES during the first year. Analysis of patients from ARRIVE I and 2 showed that most (73%) were in the lowest risk category, with 25% in the moderate risk category. Less than 2% were at highest risk of developing ST. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:541 / 545
页数:5
相关论文
共 17 条
  • [1] Clinical end points in coronary stent trials - A case for standardized definitions
    Cutlip, Donald E.
    Windecker, Stephan
    Mehran, Roxana
    Boam, Ashley
    Cohen, David J.
    van Es, Gerrit-Anne
    Steg, P. Gabriel
    Morel, Marie-angele
    Mauri, Laura
    Vranckx, Pascal
    McFadden, Eugene
    Lansky, Alexandra
    Hamon, Martial
    Krucoff, Mitchell W.
    Serruys, Patrick W.
    [J]. CIRCULATION, 2007, 115 (17) : 2344 - 2351
  • [2] Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eisenstein, Eric L.
    Anstrom, Kevin J.
    Kong, David F.
    Shaw, Linda K.
    Tuttle, Robert H.
    Mark, Daniel B.
    Kramer, Judith M.
    Harrington, Robert A.
    Matchar, David B.
    Kandzari, David E.
    Peterson, Eric D.
    Schulman, Kevin A.
    Califf, Robert M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02): : 159 - 168
  • [3] Gottschall Carlos A M, 2006, J Invasive Cardiol, V18, P22
  • [4] Hioki Y, 2001, EUR HEART J, V22, P56
  • [5] Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents
    Iakovou, I
    Schmidt, T
    Bonizzoni, E
    Ge, L
    Sangiorgi, GM
    Stankovic, G
    Airoldi, F
    Chieffo, A
    Montorfano, M
    Carlino, M
    Michev, I
    Corvaja, N
    Briguori, C
    Gerckens, U
    Grube, E
    Colombo, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17): : 2126 - 2130
  • [6] 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention
    King, Spencer B., III
    Smith, Sidney C., Jr.
    Hirshfeld, John W., Jr.
    Jacobs, Alice K.
    Morrison, Douglass A.
    Williams, David O.
    Feldman, Ted E.
    Kern, Morton J.
    O'Neill, William W.
    Schaff, Hartzell V.
    Whitlow, Patrick L.
    Adams, Cynthia D.
    Anderson, Jeffrey L.
    Buller, Christopher E.
    Creager, Mark A.
    Ettinger, Steven M.
    Halperin, Jonathan L.
    Hunt, Sharon A.
    Krumholz, Harlan M.
    Kushner, Frederick G.
    Lytle, Bruce W.
    Nishimura, Rick
    Page, Richard L.
    Riegel, Barbara
    Tarkington, Lynn G.
    Yancy, Clyde W.
    [J]. CIRCULATION, 2008, 117 (02) : 261 - 295
  • [7] LASALA JM, 2007, TRANSC CARD THER WAS
  • [8] LASALA JM, 2008, CATHETER CARDIO 0421
  • [9] Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients - The EVASTENT matched-cohort registry
    Machecourt, Jacques
    Danchin, Nicolas
    Lablanche, Jean Marc
    Fauvel, Jean Marie
    Bonnet, Jean Louis
    Marliere, Stephanie
    Foote, Alison
    Quesada, Jean Louis
    Eltchaninoff, Helene
    Vanzetto, Gerald
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (06) : 501 - 508
  • [10] Late angiographic stent thrombosis (LAST) events with drug-eluting stents
    Ong, ATL
    McFadden, EP
    Regar, E
    de Jaegere, PPT
    van Domburg, RT
    Serruys, PW
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (12) : 2088 - 2092